Trial Profile

A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants with Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SNV 1521 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Synnovation Therapeutics

Most Recent Events

13 Mar 2025 Planned number of patients changed from 76 to 200.
11 Mar 2024 According to a Synnovation Therapeutics media release, The Phase I trial, which is being led by Timothy Yap, M.D., Ph.D.,is designed to assess proof-of-concept with SNV1521 as an oral monotherapy in a dose escalation and preliminary efficacy expansion study.
11 Mar 2024 According to a Synnovation Therapeutics media release, the first patient has been dosed in a Phase I trial evaluating SNV1521 in patients with solid tumors.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com